BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35140212)

  • 1. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance.
    Lebeau PF; Byun JH; Platko K; Saliba P; Sguazzin M; MacDonald ME; Paré G; Steinberg GR; Janssen LJ; Igdoura SA; Tarnopolsky MA; Wayne Chen SR; Seidah NG; Magolan J; Austin RC
    Nat Commun; 2022 Feb; 13(1):770. PubMed ID: 35140212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
    Lebeau P; Al-Hashimi A; Sood S; Lhoták Š; Yu P; Gyulay G; Paré G; Chen SR; Trigatti B; Prat A; Seidah NG; Austin RC
    J Biol Chem; 2017 Jan; 292(4):1510-1523. PubMed ID: 27909053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
    Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
    J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
    Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
    J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
    Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
    Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells.
    Choi HK; Hwang JT; Nam TG; Kim SH; Min DK; Park SW; Chung MY
    Food Funct; 2017 Dec; 8(12):4582-4591. PubMed ID: 29130084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
    Dong B; Singh AB; Fung C; Kan K; Liu J
    Atherosclerosis; 2014 Aug; 235(2):449-62. PubMed ID: 24950000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
    Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network.
    Chae HS; You BH; Kim DY; Lee H; Ko HW; Ko HJ; Choi YH; Choi SS; Chin YW
    Sci Rep; 2018 Apr; 8(1):6737. PubMed ID: 29712938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
    PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
    Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
    Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model.
    Dandan M; Han J; Mann S; Kim R; Mohammed H; Nyangau E; Hellerstein M
    Arterioscler Thromb Vasc Biol; 2021 Dec; 41(12):2866-2876. PubMed ID: 34615375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
    PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.